SAN ANTONIO--(BUSINESS WIRE)--GenSpera, Inc. (OTC/QB: GNSZ), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, is providing an update on its clinical development programs and corporate developments.
The Company also announced that a poster entitled “Phase II study of mipsagargin (G-202), a PSMA-activated prodrug targeting the tumor endothelium, in adult patients with recurrent or progressive glioblastoma” will be presented at the 20th Annual Society for Neuro-Oncology Annual Scientific Meeting and Education Day on Friday, November 20, by Principal Investigator David Piccioni, MD, PhD, of the University of California, San Diego.
Help employers find you! Check out all the jobs and post your resume.
The Company also announced that a poster entitled “Phase II study of mipsagargin (G-202), a PSMA-activated prodrug targeting the tumor endothelium, in adult patients with recurrent or progressive glioblastoma” will be presented at the 20th Annual Society for Neuro-Oncology Annual Scientific Meeting and Education Day on Friday, November 20, by Principal Investigator David Piccioni, MD, PhD, of the University of California, San Diego.
Help employers find you! Check out all the jobs and post your resume.
